Sanofi, a global healthcare company, completed the investment in Graviton Bioscience, a clinical-stage drug discovery and development firm. Financial terms were not disclosed. "This investment in Graviton Bioscience reflects our commitment to innovative therapies and providing patients with novel medicines and vaccines. Graviton's scientific expertise in discovering and developing the next wave of innovation has the potential to significantly enhance the landscape of therapeutic possibilities," Paul Hudson, Sanofi CEO.